Astrazeneca Pharma India Ltd is Rated Sell

Understanding the Current Rating

The current Sell rating assigned to Astrazeneca Pharma India Ltd indicates a cautious stance for investors. This recommendation is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall assessment of the stock’s attractiveness and risk profile in the present market environment.

Quality Assessment

As of 14 April 2026, Astrazeneca Pharma India Ltd maintains a good quality grade. This reflects the company’s solid operational foundation and consistent business model within the Pharmaceuticals & Biotechnology sector. The firm’s return on equity (ROE) stands at a robust 26.1%, signalling effective utilisation of shareholder capital. Despite this, recent quarterly results have shown some softness, with the profit after tax (PAT) for the December 2025 quarter falling by 45.6% compared to the previous four-quarter average. This decline in profitability tempers the otherwise strong quality indicators.

Valuation Considerations

The valuation grade for Astrazeneca Pharma India Ltd is currently rated as very expensive. The stock trades at a price-to-book (P/B) ratio of 27.3, which is significantly higher than the average valuations of its pharmaceutical peers. This premium valuation suggests that the market has priced in high growth expectations. However, the company’s price-to-earnings-to-growth (PEG) ratio is 6.4, indicating that earnings growth may not justify the elevated price levels. Investors should be wary of the risk that the stock’s lofty valuation may not be supported by corresponding earnings momentum.

Financial Trend Analysis

The financial trend for Astrazeneca Pharma India Ltd is assessed as flat. The latest data shows that while the company’s profits have increased by 16.3% over the past year, the stock’s total return over the same period is a modest 3.22%. Additionally, cash and cash equivalents have declined to ₹399.94 crores in the half-year period, and the profit before depreciation, interest, and taxes (PBDIT) for the recent quarter is at a low of ₹44.83 crores. These indicators suggest limited financial momentum, which contributes to the cautious rating.

Technical Outlook

From a technical perspective, Astrazeneca Pharma India Ltd holds a mildly bearish grade. The stock has experienced mixed price movements recently, with a one-day gain of 5.21% and a one-week increase of 12.28%, but a six-month decline of 5.39% and a year-to-date drop of 3.18%. This volatility and lack of clear upward momentum in the charts underpin the technical caution reflected in the current rating.

Summary for Investors

In summary, the Sell rating on Astrazeneca Pharma India Ltd reflects a combination of strong quality metrics offset by expensive valuation, flat financial trends, and a cautious technical outlook. Investors should consider these factors carefully when evaluating the stock’s potential in their portfolios. The elevated valuation, in particular, suggests limited upside relative to risk, while the recent softness in earnings and technical signals advises prudence.

Contextualising Astrazeneca Pharma India Ltd’s Performance

Pharmaceutical stocks often face valuation pressures due to regulatory risks, patent expiries, and competitive dynamics. Astrazeneca Pharma India Ltd’s current valuation premium reflects investor optimism about its growth prospects and product pipeline. However, the flat financial trend and recent quarterly earnings decline highlight challenges in sustaining profitability. The company’s market capitalisation remains in the smallcap segment, which can add to volatility and liquidity considerations for investors.

Returns and Market Behaviour

As of 14 April 2026, the stock has delivered a one-year return of 3.22%, which is modest relative to broader market indices and some sector peers. Shorter-term returns have been more positive, with a 12.28% gain over the past week and a 5.21% increase in the last trading day, indicating some recent buying interest. However, the six-month return of -5.39% and year-to-date decline of -3.18% suggest underlying weakness. This mixed performance aligns with the mildly bearish technical grade and supports the cautious stance.

What the Mojo Score Indicates

The MarketsMOJO score for Astrazeneca Pharma India Ltd currently stands at 42.0, down from 54.0 at the start of the year. This 12-point decline reflects the combined impact of valuation pressures, flat financial trends, and technical signals. The Mojo Grade of Sell is a quantitative summary of these factors, signalling that investors may want to consider reducing exposure or avoiding new positions until fundamentals improve.

Investor Takeaway

For investors, the current Sell rating serves as a reminder to weigh Astrazeneca Pharma India Ltd’s strong quality metrics against its expensive valuation and subdued financial momentum. While the company’s high ROE and sector positioning are positives, the risk of valuation correction and earnings volatility cannot be ignored. Monitoring upcoming quarterly results and market developments will be crucial for reassessing the stock’s outlook.

Conclusion

In conclusion, Astrazeneca Pharma India Ltd’s Sell rating by MarketsMOJO, last updated on 02 Jan 2026, reflects a balanced but cautious view based on current data as of 14 April 2026. Investors should approach the stock with prudence, considering the interplay of quality, valuation, financial trends, and technical factors that shape its investment profile today.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →